SCHEDULE 13G/A: FMR LLC and Abigail Johnson Disclose 10.4% Passive Stake in Crinetics Pharmaceuticals

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a combined beneficial ownership of 10.4% of Crinetics Pharmaceuticals Inc.'s common stock as of January 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson jointly reported beneficial ownership of 9,631,637.83 shares of Crinetics Pharmaceuticals Inc. common stock.
• This ownership represents 10.4% of the total outstanding common stock of Crinetics Pharmaceuticals Inc.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating a change in previously reported ownership or status.
• The shares are held in the ordinary course of business and were not acquired or held for the purpose of changing or influencing control of the issuer.
• FMR LLC, a Delaware-based parent holding company, and Abigail P. Johnson, an individual, are the reporting persons.
• Fidelity Management & Research Company LLC, a subsidiary of FMR LLC, is identified as beneficially owning 5% or greater of the outstanding shares.
• Abigail P. Johnson is a Director, Chairman, and Chief Executive Officer of FMR LLC, and members of the Johnson family are predominant owners of FMR LLC's Series B voting common shares, forming a controlling group.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, indicating a passive investment stake. It does not contain information that would inherently suggest positive or negative sentiment regarding the issuer's operational performance or future prospects.

Positives

• The disclosure of a significant stake by a major institutional investor like FMR LLC can be perceived as a vote of confidence in Crinetics Pharmaceuticals Inc.

Risks

• While the filing states the shares are held for passive investment purposes, a large concentration of ownership by a single entity or group could, in other contexts, present a risk of influence, though explicitly disclaimed here.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Crinetics Pharmaceuticals Inc.'s future performance or outlook.

Industry Context

FMR LLC is a prominent global asset management firm. Their investment in Crinetics Pharmaceuticals Inc., a company in the biotechnology and pharmaceutical sector, reflects a typical portfolio allocation strategy for large institutional investors. This filing itself does not provide specific industry analysis but places Crinetics within the broader investment landscape for such firms.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional shareholder's stake, potentially influencing market perception and investor confidence.
• Management: Awareness of a large, passive institutional holder, which may influence investor relations strategies.

Key Dates

Keywords

Crinetics Pharmaceuticals Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Pharmaceuticals, Biotechnology, Passive Investment